Description
Capivast 200 MG is a targeted oncology medicine with the active ingredient capivasertib, an advanced AKT inhibitor for the treatment of certain kinds of advanced or metastatic breast cancer. Everest Pharmaceuticals Ltd. makes this drug to assist control malignancies driven by aberrant cell signaling pathways that cause tumors to grow and survive out of control.
Capivast 200 MG is a precision targeted therapy that works differently from conventional chemotherapy. It is designed to interrupt certain biochemical pathways that play a role in cancer progression. It is frequently used in combination with Fulvestrant in individuals with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, particularly in those patients whose disease has progressed after endocrine therapy.
Capivasertib is a significant treatment option for patients with tumours harbouring particular genetic abnormalities, including PIK3CA, AKT1 or PTEN mutations. The CAPIVAST 200 MG prevents the growth and spread of cancer cells by targeting the AKT signaling pathway and also increases the effectiveness of hormone-based therapies to fight against cancer.
What is Capivasertib?
Capivasertib is an emerging targeted medicine for cancer with a class of AKT inhibitors. The protein AKT belongs to the PI3K/AKT signaling system, which controls basic cellular activities, such as growth, metabolism, proliferation and survival.
In many malignancies, especially advanced breast tumors, genetic abnormalities lead to this pathway being turned on in the wrong way. During this time, cancer cells grow and reproduce uncontrollably, reject natural cell death mechanisms, and resist several hormone therapy .
Capivast 200 MG blocks the AKT protein and disrupts these aberrant signals. Thus, cancer cell development can be inhibited, tumor progression can be decreased and therapy response can be enhanced.
Capivast 200 MG Medical Uses
CAPIVAST 200 MG is mainly used in oncology for the treatment of:
HR-Positive, HER2-Negative Advanced Breast Cancer
Used to treat adults with hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer whose disease has progressed after previous endocrine therapy.
Combination Therapy with Fulvestrant
Capivast 200 MG is widely prescribed alongside Fulvestrant, a hormone therapy medicine that acts by preventing the effects of estrogen on breast cancer cells. The combination provides a dual mode of action against hormone-driven cancers.
Treatment for Certain Genetic Changes
Patients with the following tumor mutations may particularly benefit from treatment with Capivasertib:
- PIK3CA mutatons
- Mutations in AKT1
- PTEN changes
These mutations often help the cancer to develop and become resistant to prior hormonal therapy. CAPIVAST 200 MG works directly on these molecular defects.
How Capivast 200 MG Acts
Capivast 200 MG is a molecule that inhibits the AKT signaling pathway which is one of the main driving forces of many malignancies. The PI3K/AKT pathway regulates cell growth, division and survival. In cancer cells with aberrant mutations this route is hyperactive and allows tumors to proliferate aggressively.
Capivasertib inhibits AKT activation meaning it:
- Reduces cancer cell survival signaling
- Inhibits tumor cell proliferation
- Increases sensitivity to endocrine therapy
- Supports slowing disease progression
- May decrease resistance to therapy
Capivast 200 MG is a targeted therapy, not a traditional chemotherapy. Targeted therapies target the molecular aberrations unique to cancer, not the rapidly dividing healthy cells.
Dosage & Administration
Capivast 200 MG should be taken as prescribed by an oncologist or healthcare provider.
Standard Dosing Schedule
Capivasertib is often given in an intermittent treatment schedule:
- Twice a day
- About 12 hours separated them
- For 4 days straight
- Then 3 days without medicine
This weekly cycle allows the body to heal while still being therapeutically effective.
Administration Instructions
- Swallow the pills whole with water
- Take with or without meals as directed.
- Do not break, chew, crush, or divide tablets
- Do not take broken or damaged tablets
- Follow the suggested regimen closely
What to Do If You Miss a Dose
If you miss a dosage or if you throw up soon after taking the medicine:
- Do not take an extra replacement dosage
- Resume therapy with next scheduled dose
- If you miss a dosage, check with your healthcare professional to find out what to do.
Patients should never change the timing of their doses without physician supervision.
Capivast 200 MG Benefits
Some of the possible benefits of Capivast 200 MG in the treatment of advanced breast cancer are:
Act with Pinpoint Precision
The drug targets aberrant AKT pathway activity that is linked to cancer progression.
Non-Chemotherapy Therapy
Capivasertib is a molecular targeted therapy, which targets specific signaling pathways in cancer, and is unlike traditional chemotherapy.
Better Combination Therapy Results
In combination with Fulvestrant, Capivast 200 MG may improve the response to treatment and progression-free survival in eligible patients.
Overcoming Resistance to Hormone Therapy
The medicine may assist to re-sensitize people with cancer that has ceased responding to previous hormone-based treatments.
Easy to swallow
Capivast 200 MG is given orally and so patients can be treated outside the hospital without the need for intravenous infusions.
Common Capivast 200 MG Side Effects
As with many cancer treatments, CAPIVAST 200 MG might cause negative effects. Some patients may have modest symptoms while others may develop more serious issues that require medical intervention.
Diarrhoea
One of the most common adverse effects is severe diarrhea and this can lead to dehydration if not managed.
Skin Eruption
Skin responses can occur, especially on the hands and feet. Rashes can range from moderate discomfort to a more significant inflammatory reaction.
High blood sugar
Capivast 200 MG may increase blood sugar levels especially in those with diabetes or already having glucose intolerance.
Tiredness
Tiredness or weakness may continue during treatment.
Nausea & Vomiting
Possible digestive upset, nausea and sometimes vomiting during therapy.
Mouth ulcers
Some people may have inflammation or ulcers inside the mouth.
Precautions and Warnings
Blood Sugar Testing
Capivasertib can increase your blood sugar, therefore you may need to check your fasting blood sugar regularly while you are taking it.
Danger of Dehydration
Severe diarrhea can lead to dehydration and electrolyte imbalance. Patients should drink plenty of fluids and contact us promptly if symptoms continue.
Toxicity (skin)
Tell your healthcare provider right away if you have any severe rash, blistering, or peeling skin.
Pregnancy and lactation
Capivast 200 MG is unsafe to use during pregnancy. Patients should be warned against pregnancy during therapy and to use contraception as appropriate.
Breastfeeding is not encouraged during treatment.
Liver and Renal Function
Liver and renal impairment. Patients with liver or kidney impairment may require frequent monitoring and adjustment of dosage.
Drug Interactions
CAPIVAST 200 MG may interact with drugs that affect the CYP3A enzyme system.
Inhibitors of CYP3A
Capivasertib may interact with CYP3A inhibitors which may increase the levels of Capivasertib in the body and increase the risk of toxicity.
- There are few examples:
- Antimycotic agents
- Antibiotics (antibiotics)
- Antiviral medicines
Inductors CYP3A
Capivasertib may have less activity in combination with strong CYP3A inducers.
Examples are:
- Some seizure medications
- Rifampicin
- Herbal supplements (e.g. St. John’s Wort
Patients should always give their healthcare provider a complete list of drugs, vitamins, and supplements before starting treatment.
Storage Instructions
To ensure quality and efficiency of the product:
- Storage at 25°C
- Store in a cool, dry area
- Keep away from dampness and direct sunshine
- Keep away from children and pets
- Do not use expired medicine
Summary
Capivast 200 MG is an important step forward in the targeted treatment of HR-positive, HER2-negative advanced/metastatic breast cancer patients. Capivasertib targets the AKT signaling system to inhibit key cancer growth processes linked with genetic changes such as PIK3CA, AKT1 and PTEN mutations.
Its method of action is targeted and it can be used orally and in combination with endocrine therapy, therefore providing a valuable option for individuals whose condition has advanced following prior hormonal treatment. However, Capivast 200 MG should be used under the guidance of an experienced oncology specialist due to the possibility of major side effects and drug interactions.
Patients receiving Capivast 200 MG should be closely monitored, strictly adhere to the medication regimen, and constantly communicate with the healthcare team to ensure the safest and most effective treatment outcomes.
